Allogeneic Hematopoietic Stem Cell Transplantation with Clofarabine/Busulfan × 4 (CloBu4) Conditioning Exhibits Significant Anti-Tumor Activity In Non - Remission Hematologic Malignancies, Especially In AML
Shin Mineishi(University of Alabama at Birmingham), John E. Levine(Icahn School of Medicine at Mount Sinai), Hiromi Tobai(NHS Blood and Transplant), Attaphol Pawarode(University of Michigan), James L.M. Ferrara(Tisch Hospital), Harry P. Erba(Michigan Center for Translational Pathology), Sung Won Choi(University of Michigan), Carrie L. Kitko(Vanderbilt University Medical Center), Pavan Reddy(Wichita State University), Gregory A. Yanik(University of Michigan), Lisa Kujawski, Edward Peres(Henry Ford Hospital), John Magenau(University of Michigan)
Cited by 15
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735